GDP LLC has significantly strengthened its position in the budget market in 2021
According to the results of 2021, GDP LLC entered the top 10 distributors of the budget market, taking, according to the analytical company Headway, the eighth place. The amount of auctions won by the company amounted to 13.8 billion rubles (1.6% of the total). For comparison, in 2020, GDP LLC occupied 21 lines with 5.2 billion rubles (0.7% of the total volume). Thus, during the year the company has significantly strengthened its position in the state segment.
In hospital purchases in 2021, GDP LLC took the fourth position with 9.4 billion rubles and a share of 2.6% against the 13th place, 3 billion rubles and a share of 1.1% in 2020.
In preferential purchases according to the results of 2021, GDP LLC was in 13th place, the amount of auctions won amounted to 4 billion rubles, and the share was 0.9%.
At the same time, in the Volga Federal District, GDP LLC continues to maintain a leading position. By the end of 2021, the company ranked second with 5.4 billion rubles. That is, this federal district accounts for almost 40% of all tender purchases of GDP LLC. The company also has strong positions in the Central, Siberian and Ural Federal Districts.
Vladimir Nesterenko: support of the healthcare system is becoming a separate activity of many pharmaceutical companies
One of the key trends of the modern economy is the improvement of the healthcare system. In this context, pharmaceutical market players can no longer be limited to just the sale and promotion of medicines. This was stated by the managing partner of GDP LLC Vladimir Nesterenko in the column of the magazine GxP news.
"Of course, the fight against coronavirus has become a powerful incentive for the development of the ESG agenda in the pharmaceutical industry. Let's remember what happened in the first year of the pandemic. There were not enough beds and equipment everywhere, patients with chronic diseases did not receive the necessary treatment, medical examinations were suspended, and the implementation of state programs was under threat. At the height of the COVID-19 pandemic, when many clinics were in dire need of consumables and equipment, advanced pharmaceutical companies in developed countries sought to provide maximum support to medical organizations so that patients would not be deprived of the necessary medical care, - said Vladimir Nesterenko. - For example, we have purchased and transferred ultrasound scanning equipment, mobile X-ray systems, disinfection equipment, tomographs and much more to medical institutions of the Republic of Dagestan and the Moscow region. With such an action, on the one hand, we supported our partners, and on the other, we contributed to improving the technological state of the healthcare system in these regions and ensuring conditions in which everyone can receive the medical care they need at any time and regardless of anything."
According to him, now projects related to the support of the healthcare system are becoming a separate activity of many pharmaceutical manufacturers and distributors. JP is no exception. "Support of medical institutions has become a regular practice for us. For example, at the end of last year we supported the Children's City Hospital No. 8 in Kazan by supplying recirculators to the medical institution. There are new formats for the implementation of the ESG agenda, such as the organization of charity concerts and other events in favor of medical institutions, cooperation with charitable foundations and much more," Vladimir Nesterenko stressed.
In his opinion, in modern conditions, sustainable development programs for the pharmaceutical business should be expressed precisely in the systematic support of the healthcare industry. "And this is an absolutely logical trend - after all, in the end, a well-developed and well-equipped medical infrastructure contributes to the effective development of the market for the supply of medicines and equipment," Vladimir Nesterenko said.
GDP LLC in the 1st half of 2021 took the fourth place in public procurement
According to the results of the 1st half of 2021, GDP LLC entered the top 5 Russian distributors in terms of public procurement, taking fourth place with a share of 3.5%. This is evidenced by the data of the analytical company DSM.
The growth driver in 2021 is the state segment. Its dynamics significantly exceeds the growth in sales volumes in the pharmacy segment. Thus, according to the results of the first six months, state purchases of pharmaceuticals (privileged segment and provision of hospitals) amounted to 402 billion rubles, which is 31% more than in 2020. The pharmacy market for the same period in the prices of distributors was at the level of 542 billion rubles, which is 1% lower than in January-June 2020. Thus, there is a multidirectional dynamics of the state and retail channels. This allows companies that are actively represented in tenders to grow at a higher rate, notes DSM.
Of the total market volume, the share of GDP LLC was 1.7% (16.18 billion rubles), which secured the company the 14th place. At the same time, the increase by the 1st half of 2020 amounted to 28%.
LLC GDP became the leader in budgetary supplies in the Volga Federal District
According to the results of the 1st quarter of 2021, LLC GDP took the seventh place in the market for tender purchases of medicines. The amount of contracts concluded by the company amounted to RUB 3.07 billion. (share of the total volume - 1.6%). This is evidenced by the data of the Headway group of companies. For comparison, LLC GDP completed 2020 with a share of 0.7% (5.2 billion rubles), being on the 21st place. Thus, the company has noticeably strengthened its position in the budget market.
At the same time, in hospital purchases, LLC GDP took the fourth position with a share of 2.6% (1.88 billion rubles), in preferential purchases, it was 14th with 1% (1.14 billion rubles).
About half of all won auctions of LLC GDP - 1.5 billion rubles. - fell on the Volga Federal District. This allowed the company to become a leader among suppliers in the region.
LLC GDP began to actively participate in public procurement only in the second half of 2019. In the next three years, the company intends to enter the top 5 largest distributors in Russia.
LLC GDP became one of the leaders in the supply of anticoagulants in 2020.
LLC GDP entered the top 10 Russian distributors for the supply of anticoagulants at the end of 2020, taking the tenth line with a share of 2%. This is evidenced by the research data of the Headway group of companies.
In total, the volume of completed auctions for the supply of anticoagulants in 2020 amounted to 42.6 billion rubles, which is 149% more compared to 2019.This huge increase is associated with procurement policy amid the spread of coronavirus. For comparison, at the end of 2019, the budgetary anticoagulant market grew by 22%, in 2018 - by 52%.
In terms of regions in terms of contracts, the Volga Federal District was in the lead with 24%, the Central Federal District was in second position with 14%, the third line was shared by Moscow and the Siberian Federal District with 11%.
LLC GDP is among the largest distributors in Russia
According to the results of 2020, LLC GDP became one of the largest distributors in Russia, taking the tenth position. According to RNC Pharma, the company's share in the final shipments to the point of final sale of drugs was 1.8%.
“The last year for the Russian pharmaceutical market has passed under the sign of excitement and shortages. Both of these phenomena are unconditional evil for all market participants, and distributors are no exception. However, it must be admitted that wholesalers are the few participants in the system of commodity circulation who can at least try to turn the situation to their advantage, ”says the RNC Pharma study.
In the coming years, LLC GDP intends to enter the top 5 largest distributors in Russia. Currently, the priority nosologies for the company are oncology and pulmonology, as well as orphan diseases. Much attention is also paid to antibacterial drugs.
GDP LLC ranks 14th in hospital procurement
As of 2Q20, GDP LLC features in the top 50 suppliers of the state-financed market, ranking 14th. This is evidenced by Headway data. The contracts awarded amount to RUB 1.5 bln (a share of 1.5%). In the hospital segment, however, GDP LLC holds a share of 1.8%, where the total value of contracts awarded to the company stands at RUB 0.9 bln.
GDP LLC has started taking an active part in government procurements only since 2H19. As of the year-end, the company has executed contracts to a total of RUB 1.7 bln.
GDP LLC intends to enter the top 5 largest Russian distributors in the next three years. The company plans to develop both commercial and state-financed avenues of its business. At the same time, the primary focus in the state-financed segment will be on procurements for health insurance fund. The company’s current priority nosologies include oncology, pulmonology, antibacterial therapy and orphan diseases.https://www.hwcompany.ru/blog/expert/analiti4eskiy_
In 7 months of 2020, GDP LLC concludes RUB 5 bln worth of contracts
From January to July 2020, GDP LLC has been awarded contracts totalling RUB 5 bln. Almost half of that figure — RUB 2.3 bln — corresponds to contracts for the supply of medications, medical equipment and medical products used in the fight against COVID-19.
Main customers — the Single Customer Directorate of the Ministry of Health of the Moscow Region and Mosoblmedservice, the supplier of public clinics in the region. With the former, GDP LLC has concluded antiepidemic contracts in the amount of RUB 1.65 bln; with the latter — of RUB 261.2 mln. The total value of contracts with the two largest customers of the region stands at approximately RUB1.9 bln.
GDP LLC became an active participant of the government contracts market in the second half of 2019. As of the year-end, the Company had been awarded contracts totalling RUB 1.7 bln. Whereas in 2019, the main supplies involved medical equipment, in 2020, a number of contracts were concluded for the supply of expensive innovative medications. The company became a supplier of the Ministry of Health for the first time, under the Nosologies Programme. In January 2020, the distributor won the tender for supplies of Alemtuzumab medication for disseminated sclerosis in the amount of RUB 573.4 mln. Contracts were also concluded for the supply of antineoplastic agents Nivolumab (RUB 383.6 mln), Bevacizumab (RUB 216 mln) and Ipilimumab (RUB 98.7 mln). According to GDP LLC CEO, Vladimir Nesterenko, the company’s strategic task for the next three years is to become a top 5 distributor in Russia.https://pharmvestnik.ru/content/news/Podkontrolnaya-36-6-kompaniya-stala-krupnym-postavshikom-Moskovskoi-oblasti-vo-vremya-epidemii.html
20 January 2020
GDP LLC delivers the medication for disseminated sclerosis patients as part of the 14 Nosologies State Programme
GDP LLC won the tender to supply the Russian Health Ministry with Alemtuzumab as part of the 14 Nosologies Programme (14 NP) under a contract initially worth RUB 573.4 mln. The company offered to perform the contract at the initial price of RUB573.4 mln. It is the first contract between GDP LLC and the Russian Health Ministry under the 14 Nosologies Programme.
Alemtuzumab for disseminated sclerosis is included in the list of 14 Nosologies Programme for 2020 and is purchased by the Health Ministry for the first time. Lemtrada, with this international non-proprietary name, is produced by Sanofi and packaged at Nanolek LLC’s Russian facilities.
Disseminated sclerosis — is a chronic autoimmune disorder in which the myelin insulating covering of nerve cells in the brain and spinal cord becomes damaged. The damaged parts are subject to scarring. The disease can cause a variety of symptoms, including paralysis, difficulties with balance, cognitive disorders, changes in sensation and visual problems due to optic neuritis. The disease occurs in younger people between the age of 15 and 40.
According to the Russian Ministry of Health, disseminated sclerosis cases have become more numerous in recent years. In 2013, for example, there were 62.3 thousand patients, but by 2019, their number had increased to 85.2 thousand.https://vademec.ru/news/2020/01/20/dochka-36-6-postavit-minzdravu-alemtuzumab-po-gosprogramme-14-vzn-na-573-4-mln-rubley
27 August 2019
GDP LLC enters top 10 Russian distributors
As of the first half of 2019, GDP LLC features in the top 10 distributors of Russia, ranking 9th. According to RNC Pharma, the company share in final shipments to final retail points of medications sale now stands at 2.9%, evidencing that GDP LLC has strengthened its position. For comparison, as of the first half of 2019, the company share was at about 2.8%.
GDP LLC intends to enter the top 5 largest Russian distributors in the next three years. The company’s current priority nosologies include oncology, pulmonology, antibacterial therapy and orphan diseases.https://rncph.ru/news/27_08_2019